跳转至内容
Merck
CN

A7986

阿托伐醌

≥98% (HPLC), powder, anti-protozoal agent

别名:

Mepron, 反式-2-[4-(4-氯苯基)环己基]-3-羟基-1,4-萘二酮

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C22H19ClO3
化学文摘社编号:
分子量:
366.84
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

阿托伐醌, ≥98% (HPLC)

Quality Level

assay

≥98% (HPLC)

form

powder

color

yellow

solubility

DMSO: >10 mg/mL

originator

GlaxoSmithKline

storage temp.

−20°C

SMILES string

OC1=C([C@H]2CC[C@@H](CC2)c3ccc(Cl)cc3)C(=O)c4ccccc4C1=O

InChI

1S/C22H19ClO3/c23-16-11-9-14(10-12-16)13-5-7-15(8-6-13)19-20(24)17-3-1-2-4-18(17)21(25)22(19)26/h1-4,9-13,15,26H,5-8H2/t13-,15-

InChI key

KUCQYCKVKVOKAY-CTYIDZIISA-N

正在寻找类似产品? 访问 产品对比指南

Application

Atovaquone inhibits the cytochrome bc(1) complex via interactions with the Rieske iron-sulfur protein and cytochrome b in the ubiquinol oxidation pocket. In addition to its use as a treatment for toxoplasmosis, atovaquone has antimalarial properties and prevents pneumocystis pneumonia post-renal transplant.

Biochem/physiol Actions

抗原生动物线粒体电子传递抑制剂中的阿托伐醌。 它还具有抗疟药和抗肺囊虫药的作用。
阿托伐醌是一种抗原生动物线粒体电子传递抑制剂;抗疟药;抗肺囊虫药,也已用于治疗弓形虫病。它是原生动物线粒体蛋白泛醌的类似物,并通过与泛醇氧化口袋中的Rieske铁硫蛋白和细胞色素b相互作用抑制细胞色素bc(1)复合物起作用。

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品

此项目有


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Steven Gabardi et al.
Clinical transplantation, 26(3), E184-E190 (2012-04-11)
Pneumocystis pneumonia (PCP) is associated with significant morbidity and mortality in renal transplant recipients (RTR). Trimethoprim-sulfamethoxazole (TMP-SMZ) is considered the prophylactic agent-of-choice. Some patients require an alternative owing to TMP-SMZ intolerance. This is the first evaluation of full-dose atovaquone vs.
Kai J Rogers et al.
Cell reports, 30(12), 4041-4051 (2020-03-27)
During the 2013-2016 Ebola virus (EBOV) epidemic, a significant number of patients admitted to Ebola treatment units were co-infected with Plasmodium falciparum, a predominant agent of malaria. However, there is no consensus on how malaria impacts EBOV infection. The effect
Nehal Gupta et al.
Pharmaceuticals (Basel, Switzerland), 14(6) (2021-06-03)
Triple-negative breast cancer (TNBC) is considered to be the most aggressive and malignant neoplasm and is highly metastatic in nature. In the current study, we investigated the anti-metastatic potential of atovaquone, a protozoal drug prescribed for Pneumocystis pneumonia. We showed
Zehua Song et al.
Biochimica et biophysica acta, 1847(12), 1487-1494 (2015-08-25)
The respiratory chain bc1 complex is central to mitochondrial bioenergetics and the target of antiprotozoals. We characterized a modified yeast bc1 complex that more closely resemble Plasmodium falciparum enzyme. The mutant version was generated by replacing ten cytochrome b Qo
Mikio Kimura et al.
Parasitology international, 61(3), 466-469 (2012-04-10)
Malaria remains an important health risk among travelers to tropical/subtropical regions. However, in Japan, only 2 antimalarials are licensed for clinical use - oral quinine and mefloquine. The Research Group on Chemotherapy of Tropical Diseases introduced atovaquone-proguanil in 1999, and

商品

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

全球贸易项目编号

货号GTIN
A7986-10MG04061833390894
A7986-50MG04061833390900

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持